Yu Z.,Harbin Institute of Technology |
Gu H.,China State Institute of Pharmaceutical Industry |
Gu H.,Sinopharm A think Pharmaceutical Co. |
Tang D.,Harbin Institute of Technology |
And 3 more authors.
RSC Advances | Year: 2015
This work is to fabricate thermo responsive nanofibers of which the thermo response temperatures could be easily tuned, and of which the fibrous shapes could be maintained after heating-cooling cycles in aqueous solution. The nanofibers were further fabricated into a nonwoven mat with size-variable pores for temperature controlled release of a model drug, Erlotinib. The thermo responsive nanofibers were electrospun from the copolymers of PMMA-co-PVCL (synthesized from MMA and PVCL, and had different LCSTs) by changing the solvents and the ratio of initiator/monomer. FT-IR and 1H NMR were used for molecular structural characterization; UV-vis spectra were used for LCST measurement; SEM and metalloscope were used to determine the optimal electrospinning parameters and to observe the shape maintaining abilities of the nanofibers after the heating-cooling recycles. Then, anti-cancer drug, Erlotinib, was incorporated into PMMA/PVCL nanofibers (represent as 'model I'), or put in a drug reservoir and covered with the PMMA/PVCL electrospinning mat (presented as 'model II'). UV-vis spectra were used to study the drug release behavior of each model. Results indicate that in model I, drug release was "switch on" below LCST, and "switch off" above LCST; in model II, drug release was faster above LCST than below LCST. © The Royal Society of Chemistry 2015. Source
Wang S.,Changchun University of Technology |
He L.,Sinopharm A think Pharmaceutical Co. |
Cheng G.,Changchun University of Technology
Journal of Electrical and Computer Engineering | Year: 2015
In order to strengthen the mobile Internet mobility management and cloud platform resources utilization, optimizing the cloud routing efficiency is established, based on opportunistic bacterial foraging bionics, and puts forward a chemotaxis perception of collaborative optimization QoS (Quality of Services) cloud routing mechanism. The cloud routing mechanism is based on bacterial opportunity to feed and bacterial motility and to establish the data transmission and forwarding of the bacterial population behavior characteristics. This mechanism is based on the characteristics of drug resistance of bacteria and the structure of the field, and through many iterations of the individual behavior and population behavior the bacteria can be spread to the food gathering area with a certain probability. Finally, QoS cloud routing path would be selected and optimized based on bacterial bionic optimization and hedge mapping relationship between mobile Internet node and bacterial population evolution iterations. Experimental results show that, compared with the standard dynamic routing schemes, the proposed scheme has shorter transmission delay, lower packet error ratio, QoS cloud routing loading, and QoS cloud route request overhead. © 2015 Shujuan Wang et al. Source
Liang X.-D.,Sinopharm A think Pharmaceutical Co. |
Wang S.-J.,Changchun University of Technology |
Zhang H.,Heilongjiang University |
Gu H.-J.,Sinopharm A think Pharmaceutical Co.
Chinese Journal of New Drugs | Year: 2013
Objective: To establish a method for determination of impurities in raw material of dasatinib, and to provide evidence for evaluation of dasatinib qualities. Methods: Four kinds of the impurities in dasatinib were identified using a C18 column by LC/MS. The mobile phase A was 5 mmol·L-1 formic acid solution-acetonitrile-methanol (88:6:6), mobile phase B was 5 mmol·L-1 formic acid solution-acetonitrile-methanol (10:85:5), and gradient elution was applied. Furthermore, the 4 impurities were synthesized. Results: Under the LC/MS conditions, dasatinib and its impurities were effectively separated. To prove the contained impurities, their retention times were compared with those of the respective synthetic references as well as by structural elucidation of the impurity. Conclusion: The method based on LC/MS for identification of dasatinib and its impurities has been successfully established, which is rapid, sensitive and specific. Source
Shanghai Institute of Pharmaceutical Industry and Sinopharm A think Pharmaceutical Co. | Date: 2012-06-26
Disclosed in the present invention is a novel histone deacetylase inhibitor of benzamides and use thereof. The inhibitor has good efficacy in treating diseases caused by abnormal gene expression, such as tumours, endocrine disorders, immune system diseases, genetic diseases and nerve system diseases. The histone deacetylase inhibitor of benzamides is a compound of the following general chemical structural formula (I) or a salt thereof.
Zheng Y.-D.,Sinopharm A think Pharmaceutical Co. |
Yang P.-C.,Sinopharm A think Pharmaceutical Co. |
Zhao X.,Sinopharm A think Pharmaceutical Co.
Chinese Journal of New Drugs | Year: 2015
Vorinostat, a pan-histone deacetylase inhibitor (HDACI), was approved by the US Food and Drug Administration (FDA) for use in patients with cutaneous T-cell lymphoma (CTCL) in 2006. In recent years, with the deepening of the research, vorinostat has good efficacy in the treatment for other cancers. Vorinostat in combination with gemtuzumab ozogamicin and azacitidinecan improves effective rates to 40% in the treatment of elderly patients with relapsed orrefractory acute myelogenous leukemia (AML). Vorinostat in combination with decitabine can improve effective rates to 46.2% in the treatment of relapsed or refractory acute lymphoblastic leukemia (AL). Vorinostat in combination with bortezomib intreatment for multiple myeloma (MM) may prolong progression-free survival to 7.63 months. Furthermore, vorinostat can effectively improve the immune function of patients with advanced breast cancer and bone marrow transplant. In this article, we summarized progress of vorinostat applications through reviewing foreign literature in recent years. ©, 2015, Chinese Journal of New Drugs Co. Ltd. All right reserved. Source